Issues relating to drug pricing proposals including implementation of the Inflation Reduction Act (P.L. 117-169); Rx oversight issues; PBM oversight issues.
2025 · 1st Quarter (Jan 1 - Mar 31)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by AKIN GUMP STRAUSS HAUER & FELD.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $120,000.00
- Expenses
- Not reported
- Registrant
- AKIN GUMP STRAUSS HAUER & FELD
- Filing UUID
- 27f2ec3f-29b2-4ea3-ba21-127c17085be8
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Section 301 tariffs; Issues related to IP protection; Market access issues.
Issues related to patent reform legislation; H.R. 4370/S. 2220 - The PREVAIL Act (118th Congress).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.